Brown Advisory Inc. Sells 121,951 Shares of Guardian Pharmacy Services, Inc. $GRDN

Brown Advisory Inc. cut its holdings in Guardian Pharmacy Services, Inc. (NYSE:GRDN) by 6.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,637,136 shares of the company’s stock after selling 121,951 shares during the period. Brown Advisory Inc.’s holdings in Guardian Pharmacy Services were worth $49,261,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in GRDN. Dynamic Technology Lab Private Ltd bought a new position in shares of Guardian Pharmacy Services in the 1st quarter worth about $233,000. JPMorgan Chase & Co. raised its position in shares of Guardian Pharmacy Services by 48.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock worth $128,000 after acquiring an additional 1,956 shares in the last quarter. Legal & General Group Plc raised its position in shares of Guardian Pharmacy Services by 1,783.1% in the 2nd quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock worth $317,000 after acquiring an additional 14,104 shares in the last quarter. Rhumbline Advisers raised its position in shares of Guardian Pharmacy Services by 121.1% in the 2nd quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock worth $345,000 after acquiring an additional 8,860 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Guardian Pharmacy Services in the 2nd quarter worth about $214,000.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on GRDN shares. Oppenheimer lifted their price objective on Guardian Pharmacy Services from $38.00 to $43.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Truist Financial lifted their price objective on Guardian Pharmacy Services from $38.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Weiss Ratings lowered Guardian Pharmacy Services from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Raymond James Financial reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. Finally, Bank of America initiated coverage on Guardian Pharmacy Services in a report on Monday, April 27th. They set a “buy” rating and a $42.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Guardian Pharmacy Services presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

Insiders Place Their Bets

In related news, Director Thomas J. Salentine, Jr. sold 3,570,677 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $105,977,693.36. Following the transaction, the director owned 4,469,316 shares in the company, valued at approximately $132,649,298.88. This represents a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Fred Burke sold 671,432 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $29.68, for a total value of $19,928,101.76. Following the completion of the transaction, the insider owned 840,413 shares in the company, valued at approximately $24,943,457.84. The trade was a 44.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 9,726,405 shares of company stock valued at $288,679,700 in the last quarter. 32.96% of the stock is currently owned by company insiders.

Guardian Pharmacy Services Stock Down 0.1%

Shares of NYSE GRDN opened at $43.04 on Monday. Guardian Pharmacy Services, Inc. has a twelve month low of $19.17 and a twelve month high of $43.86. The stock’s 50 day moving average price is $38.22 and its 200-day moving average price is $34.12. The company has a market capitalization of $2.14 billion, a PE ratio of 51.85, a PEG ratio of 2.83 and a beta of 0.08.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. Guardian Pharmacy Services had a return on equity of 30.72% and a net margin of 3.64%.The business had revenue of $336.60 million for the quarter, compared to the consensus estimate of $329.89 million. During the same quarter in the prior year, the business earned $0.22 earnings per share. Guardian Pharmacy Services’s revenue for the quarter was up 2.2% on a year-over-year basis. As a group, research analysts expect that Guardian Pharmacy Services, Inc. will post 1.18 EPS for the current fiscal year.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.